ARCH
Aortic Arch Related Cerebral Hazard
|
Status:
As of June 2005, 135 parients had been randoized. Trial is ongoing, and is currently recruiting both subjects and centers.
Purpose:
To compare the efficacy of anticoagulant therapy (warfarin) with that of anti-platelet therapy (aspirin in combination with clopidogrel) in preventing stroke in high-risk patients with aortic arch atheromas.
Location(s):
Australia, Europe
Year Started:
2002
Design:
Open-label, multicenter, randomized, controlled trial.
Inclusion Criteria
Patients with an ischemic stroke within 6 months, and an aortic arch atheroma that is either mobile or >= 4mm thick will be eligible for this trial.
Patient Involvement:
Patients will be randomized to receive either warfarin titrated to yield an international normalized ratio (INR) of 2.0-3.0 or 75-325 mg of aspirin plus 75 mg clopidogrel per day. Patients will be followed by 4 monthly reviews from randomization to the end of the study.
Primary Outcome:
Recurrent stroke, acute myocardial infarction, peripheral embolism, vascular death.
Source of Information:
Presented at the 28th International Stroke Conference (February 2003). Presented at 14th European Stroke Conference (May 2005). Correspondence with trial coordinator. Presented at International Stroke Conference (February 2008).
|
|
Web Links and Publications:
|
|
This information last updated on: 1/23/2009
Reviewed on: 07/16/2009.
|
Trials
Directories